Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Data from CORIST-trial to be presented at ASCO Gastrointestinal Cancers Symposium

Data with Scandion Oncology’s lead compound SCO-101 as combination therapy in patients with metastatic colorectal cancer accepted for poster presentation.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will have clinical data for its lead compound SCO-101 presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place on January 20-22, 2022. Pharmacokinetic data from part 1 of the CORIST Phase II-trial in patients with metastatic

Endomines’ Nomination Committee composition

Endomines’ Nomination Committee composition  Endomines AB, Stock Exchange Release 18 January 2022 at 11:00 CET   Endomines’ Nomination Committee represents the Company’s largest shareholders and is tasked with preparing and presenting proposals to the Annual General Meeting on the composition of the Board of Directors and Board and Auditor remuneration. The Nomination Committee consists of three members, of which two represent the major shareholders and one is the Chairman of the Board.   The following persons have been appointed to the Nomination Committee for the Annual

Correction: Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them in Penneo A/S

Company Announcement No. 2-2022Copenhagen, 18 January 2022 Transaction notification under Article 19 of the EU Market Abuse RegulationPenneo hereby announces in accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), to have received the following correction to notifications from a legal person closely associated with a person discharging managerial responsibility in Penneo. André Clément Holding ApS (Legal person closely associated with André Clément (Chief Commercial

East Capital Real Estate has sold the very popular and high-quality spa hotel, Georg Ots Spa, in Kuressaare

Fund manager East Capital Real Estate has sold the Gospa hotel building in Kuressaare, with a total area of over 6,600 square metres. The hotel is located on the attractive Saaremaa island resort, near the harbour, the city park and the picturesque 13th century Bishop’s Castle.The hotel has been sold to a company related to the operator that owns a number of high quality and popular hotels accross the region. East Capital Real Estate has managed and developed the property together with the operator since 2006 on behalf of the East Capital Baltic Property Fund. Georg Ots Spa Hotel opened

Conotoxia brings Apple Pay to multi-currency card users

Conotoxia brings its multi-currency card users Apple Pay, a safer, more secure and private way to pay that helps customers avoid handing their payment card to someone else, touching physical buttons or exchanging cash – and uses the power of iPhone and Apple Watch to protect every transaction.Users simply hold their iPhone or Apple Watch near a payment terminal to make a contactless payment. Every Apple Pay purchase is secure because it is authenticated with Face ID, Touch ID, or device passcode, as well as a one-time unique dynamic security code. Apple Pay is accepted in grocery stores,

Diamyd Medical patent for intralymphatic injection of GAD in autoimmune diabetes to be granted in China

The patent that will be granted by the Chinese Patent Office is valid until 2035. The patent primarily protects the administration method of Diamyd[®] (GAD/alum) which has shown positive results in the Phase I/II and Phase IIb trials DIAGNODE-1 and DIAGNODE-2 and will be evaluated in the Phase III trial DIAGNODE-3.Patents for intralymphatic administration of GAD to treat and prevent autoimmune diabetes including type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA) have already been approved in Europe, Japan, Russia, Australia and Israel,  with additional countries pending.

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 15 - 18 JANUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

BioStock: Coegin Pharma aims high in 2022

In 2021, Coegin Pharma reached a key milestone by launching a combined phase I/II clinical trial with AVX001 in actinic keratosis patients. Moreover, the company expanded its pipeline in order to pursue cancer indications and chronic kidney disease. BioStock reached out to Coegin’s CEO Tore Duvold to hear what he had to say about the company’s achievements during 2021 and his goals for 2022.Read the interview with Tore Duvold at biostock.se: https://www.biostock.se/en/2022/01/coegin-pharma-aims-high-in-2022/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: CLS enters 2022 raring to go

For medtech company Clinical Laserthermia System (CLS), 2021 was a year of strengthening both its organisation and its financial position. The company recruited new, experienced team members and carried out an oversubscribed rights issue ensuring a solid base for the future. CLS also demonstrated its resilience as it successfully navigated the process of finding new suppliers of sterilisation services. BioStock spoke to acting CEO Dan J. Mogren about 2021 and what we can expect from 2022.Read the interview with CLS' acting CEO Dan J. Mogren at biostock.se: https://www.biostock.se/en/2022/

Lindex thinks life needs a little more support

With this spring's underwear campaign ‘Your invisible support’, Lindex is taking the next step in the brand's successful development. The fashion company is also taking further steps in becoming even more inclusive in its assortment. Lindex is now launching its new underwear campaign 'Your invisible support'. From your teenage years to your wise years. Through falling in love for the first time to the club nights that never end. From being pregnant to the endless nights with a baby. From changes in life to finding yourself again. From leaving your job forever to helping your

Sensys Gatso has won a five-year TRaaS contract from Pelham Manor, New York worth SEK 7.9 million

Sensys Gatso Group, a global leader in traffic safety systems, through its subsidiary, Sensys Gatso USA has been selected as the automated red light enforcement provider for Pelham Manor, NY. This new managed service program is expected to generate approximately USD 875,000, corresponding to SEK 7.9 million over the five-year term.Pelham Manor is a town in Westchester County, New York, with feeder roads carrying commuters into New York City each day. The high volume of daily traffic brings red light violators to this small community, putting its residents; drivers and pedestrians, at risk.

KONE wins order to equip the Zhengzhou metro line from Zhengzhou airport to Xuchang

KONE Corporation, press release, January 18, 2022 KONE Corporation, a global leader in the elevator and escalator industry, has won an order to supply a suite of People Flow® solutions, including 37 KONE elevators, 195 KONE escalators and four KONE autowalks for Zhengzhou metro line in China from Zhengzhou airport to Xuchang.  This transit line connects Zhengzhou airport and Xuchang east station of Jian‘an District. The total length of the line is more than 35 kilometers, and it includes 16 underground stations, including five transfer stations.   KONE's delivery

The Qt Company launches digital advertising solution

New service significantly improves monetization opportunities for Qt usersEspoo, Finland – 18[th] January 2022 – The Qt Company , the leading global provider of software technology, today announces the launch of Qt Digital Advertising to help Qt users monetize UI/UX screens built with Qt. The new solution, which will significantly streamline and enhance revenue generation opportunities for mobile, desktop and embedded applications and devices, was designed to focus on monetization, productivity and disruption. For the first time ever, mobile, desktop and embedded

Changes in the Fiskars Group Leadership Team

Fiskars Corporation Stock Exchange Release January 18, 2022 at 10:00 (EET)     Changes in the Fiskars Group Leadership Team   Fiskars Group has made two changes to its Group Leadership Team to support the implementation of its previously announced growth strategy.   Charlene Patten Zappa has been appointed Executive Vice President, Business Area Terra and a member of the Fiskars Group Leadership Team. She will report to President and CEO Nathalie Ahlström and start in her position on January 18, 2022. She joins Fiskars Group from the J.M. Smucker Company, where

The Hakkapeliitta winter tire family is growing: New non-studded NOKIAN TYRES Hakkapeliitta® R5 offers unprecedented ice grip, silence and eco-friendly mobility for the Northern winter

Nokian Tyres  is continuing to renew its legendary Hakkapeliitta winter tire range. NOKIAN TYRES Hakkapeliitta® 10  has been a great success and now the world's northernmost tire manufacturer is publishing its new flagship products: Hakkapeliitta® R5 Nordic non-studded winter tires designed for passenger cars and SUVs.- Hakkapeliitta winter tires  are known around the world as the champions of demanding winter weather. The new

Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K

Cyxone (publ) announces today that the company has engaged a renowned European Contract Development & Manufacturing Organization (CDMO) for the scale-up and production of the active ingredient of its drug candidate T20K. The production will be performed in accordance with Good Manufacturing Practice (GMP), exploring a brand-new manufacturing method. The collaboration will initially cover method development and later supply material for use in non-clinical and clinical development activities.Cyxone is developing T20K, a peptide aimed for the treatment of multiple sclerosis (MS). Preclinical

Diagnostics pioneers Abacus Diagnostica, Kaivogen and Labrox are now together Uniogen

Three Finnish life science experts – Abacus Diagnostica, a frontrunner in molecular testing and rapid PCR test systems, Kaivogen, a specialist in immunoassays and antibody tests, and Labrox, an innovator of high technology laboratory instruments and diagnostic readers – announced in September 2021 that they are joining forces to form a global diagnostics pioneer. The share swap agreement between the companies has entered into force and the transaction has now been completed. The name of the new company is Uniogen Oy. The company is targeting the global market with a total solution under

Medivir’s MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamide

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) fostroxacitabine bralpamide as the official generic name for the company's patented candidate drug MIV-818, which is in clinical development in primary liver cancer. Medivir's main project, fostroxacitabine bralpamide (MIV-818), is the company’s proprietary candidate drug with a unique mechanism of action, which makes fostroxacitabine bralpamide attractive to be combined with a multitude of other drugs for the treatment

Invitation to presentation of year-end report 2021

Nobia will publish its year-end report for 2021 on Tuesday, February 1 at 08:30 CET. A webcasted telephone conference will be held the same day at 10.00 CET.Nobia’s President and CEO Jon Sintorn and CFO Kristoffer Ljungfelt will present the results and answer questions.The telephone conference will be webcasted live on Nobia’s website, or at https://edge.media-server.com/mmc/p/i4heo6dv Details for participation by telephone: Sweden:          +46 8 56 64 26 51UK:                 +44 33 33 00 08 04USA:               +1 631 913 1422Pin code:          8161 4899 # The

Azad Najar a speaker at the ICPM conference today

Today, 18 January, Realheart's founder Dr Azad Najar will be appearing at the ICPM conference in the United Arab Emirates. ICPM stands for International Conference of Pharmacy and Medicine and this is the second time Azad Najar has been invited. In addition, Realheart also has an exhibition space at the venue where the company's total artificial heart is presented.Dr Azad Najar is the founder of Realheart and the inventor behind the company's artificial heart. He is originally from Iraqi Kurdistan and has received a lot of attention for his innovation in this region. ''Worldwide, 64

Changes in the KONE Executive Board

KONE Corporation, stock exchange release, January 18, 2022 at 9.30 a.m. EET Changes in the KONE Executive Board Thomas Hinnerskov, Executive Vice President responsible for South Europe, Middle East and Africa, has decided to leave KONE for a position outside the company latest at the end of May 2022. Thomas has served as a member of KONE’s Executive Board since 2016, first as head of the Central and North Europe region and then head of the South Europe, Middle East and Africa region. The search for his successor has started. “I would like to thank Thomas for his valuable

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 17th January 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,064,137 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Inhalation Sciences submits whitepaper to FDA aiming to establish DissolvIt® as an FDA-recommended standard research method in US

(Stockholm, 17 January 2022) Inhalation Sciences (ISAB) has submitted a white paper to the US FDA (Food and Drug Administration) aiming to validate its in vitro simulated lung model DissolvIt[®] as an FDA-recommended technology, and, ultimately, a new standard research method for inhaled drug research in the US. If approved, the FDA will co-fund the project for up to 250 KUSD (approx. 2.2 MSEK) on an annual basis for up to two years. A final decision on approval for the submitted whitepaper is expected in September 2022.Inhalation Sciences has submitted a formal whitepaper to the FDA’s

Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis

Company release, Inside information18 January 2022 at 9:20 a.m. (EET) Nightingale Health Plc (“Nightingale”) announces today that the company will take a major step towards its mission of empowering people to make the best decisions for their own health by combining Nightingale’s proprietary blood test with genomics. This expansion is accelerated by acquiring a Finnish genetic testing company Negen Ltd. (“Negen”) and launching an international excellence centre focusing on genetic data analysis. The first products integrating Nightingale’s proprietary blood test and genomic data will

There are no items matching the current filter
There are no more items matching the current filter
Back to top